explore
Previous article:
What does generative AI mean for health care? We asked experts
Next article: FDA's naming rule on biosimilars has undermined competition
Next article: FDA's naming rule on biosimilars has undermined competition
focus
knowledge
-
Readout Newsletter: Merck, Vertex, and Viking updates
2025-08-28 03:24 -
Patient advocates debate FDA's accelerated approval process
2025-08-28 02:34 -
Will generative AI in health care meet the fate of IBM's Dr. Watson?
2025-08-28 02:21 -
The Readout: Lenmeldy, GLP
2025-08-28 01:38 -
Abortion pill case raises question: who can sue the FDA?
2025-08-28 01:11 -
7 more heat
2025-08-28 01:00